Celgene Corp. will acquire Pharmion Corp. for $2.9 billion in a move intended to advance Celgene’s strategy to become a global leader in the hematology/oncology field. The transaction brings together Revlimid, Thalomid and Vidaza, products expected to generate multiple global revenue streams for accelerated revenue and earnings growth during the next five years. “The acquisition of Pharmion is an exceptional strategic fit that will expand our role as a leader in hematology and oncology,...